Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
NCT06517901 · View on ClinicalTrials.gov ↗
Study Summary
The MRI-targeted biopsy for prostate cancer detection can be performed using one of two techniques: 1. Software-based fusion of MRI and ultrasound images (software fusion) or 2. Visually estimated MRI-informed (cognitive fusion) technique To date, there is a lack of adequately powered RCTs directly comparing the cognitive vs fusion targeted biopsy. This randomized study will directly compare the detection rates of clinically significant prostate cancer following either the cognitive or the fusion targeted prostate biopsy in men with suspicious lesions noted on multi-parametric MRI (mp-MRI) of prostate.
Conditions Studied
Interventions
- PROCEDURE Software fusion prostate biopsy
- PROCEDURE Cognitive fusion prostate biopsy
Study Locations (4)
Massachusetts
- Lahey Clinic, Inc — Burlington
New York
- Albany Medical Center — Albany
Pennsylvania
- Pennsylvania State University — Hershey
Manitoba
- Manitoba Prostate Centre, CancerCare Manitoba — Winnipeg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,306 participants |
| Start Date | 2025-04-18 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06517901
The ClinicalTrials.gov registry entry for NCT06517901 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albany Medical College, which has 77 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions — of which Software fusion prostate biopsy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06517901 reports 4 study locations spanning 4 distinct geographic areas — top geographies include Massachusetts, New York, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06517901 about?
NCT06517901 is a clinical study titled "Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer". The MRI-targeted biopsy for prostate cancer detection can be performed using one of two techniques: 1. Software-based fusion of MRI and ultrasound images (software fusion) or 2. Visually estimated MRI-informed (cognitive fusion) technique To date, there is a lack of adequately powered RCTs directl...
What is the current status of trial NCT06517901?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,306 participants. The study started on 2025-04-18. Estimated completion is 2027-06-30.
What conditions does trial NCT06517901 study?
This clinical trial studies the following conditions: Prostate Cancer, Diagnosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06517901?
The interventions under investigation include: Software fusion prostate biopsy (PROCEDURE), Cognitive fusion prostate biopsy (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06517901?
This trial is sponsored by Albany Medical College, which has 77 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06517901 being conducted?
This trial has 4 study locations across Massachusetts, New York, Pennsylvania, Manitoba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.